Drug data last refreshed 3d ago
SUBUTEX is a sublingual tablet containing buprenorphine, a partial mu-opioid receptor agonist used to treat opioid dependence and substance use disorder. It is a foundational medication in opioid maintenance therapy, offering a safer alternative to full opioid agonists with lower abuse potential. The drug works by reducing cravings and withdrawal symptoms while providing a partial opioid effect.
Product faces imminent loss of exclusivity with moderate competitive pressure (30% rating), signaling potential team downsizing or transition focus to next-generation formulations.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Transfer of Subjects From Subutex/Suboxone to RBP-6300
Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)
A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)
Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
Worked on SUBUTEX at Indivior? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on SUBUTEX offers experience in a therapeutic area with high unmet need and strong government/payer relationships, but limited growth trajectory. The approaching LOE makes this role best suited for professionals building expertise in mature asset management, payer negotiations, and transition planning rather than commercial expansion.